Table 3 Associations between genetic risk scores and TNFi treatment response (achieving good/moderate EULAR response vs no) in overall RA, as well as in ACPA-positive RA and ACPA-negative RA

 Linear

0.96 (0.81–1.14)

1.00 (0.82–1.22)

0.89 (0.56–1.42)

 Q1

Reference

Reference

Reference

 Q2 vs Q1

0.68 (0.31–1.50)

1.00 (0.36–2.81)

0.66 (0.17–2.54)

 Q3 vs Q1

0.77 (0.37–1.60)

1.07 (0.42–2.71)

0.60 (0.15–2.36)

 Q4 vs Q1

0.79 (0.39–1.57)

1.06 (0.44–2.55)

0.95 (0.23–3.93)

 Linear

0.92 (0.77–1.12)

0.96 (0.76–1.20)

1.30 (0.80–2.12)

 Q1

Reference

Reference

Reference

 Q2 vs Q1

1.15 (0.51–2.61)

0.76 (0.22–2.65)

2.35 (0.67–8.20)

 Q3 vs Q1

1.05 (0.52–2.12)

0.89 (0.30–2.65)

2.19 (0.58–8.30)

 Q4 vs Q1

0.99 (0.48–2.02)

0.84 (0.27–2.54)

3.53 (0.88–14.22)

 Any SE

0.79 (0.59–1.06)

0.84 (0.59–1.20)

1.07 (0.53–2.17)